Related Experiment Video
Updated: May 14, 2026
Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay
Published on: September 13, 2024
Monitoring Cytogenetic Effects in Peripheral Blood Lymphocytes of Thyroid Cancer Patients Receiving Radioiodine
Igor K Khvostunov1, Elena Nasonova2, Pavel Lobachevsky2,3
1Department of Radiation Biophysics, A. Tsyb Medical Radiological Research Center (MRRC)-Branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation (NMRRC), 10, Marshal Zhukov St., 249031 Obninsk, Kaluga Region, Russia.
Abstract:
This study investigated cytogenetic damage in peripheral blood lymphocytes of 10 differentiated thyroid cancer patients who received multiple 131I radioiodine (RAI) treatments following total thyroidectomy. Blood samples were collected before the RAI therapy course and 2-3 days after the course for a few selected courses (from 1 to 3) for each patient. The cumulative average number of chromosome aberrations (CAs) per cell and its increment due to a selected RAI course were evaluated using the multiplex fluorescence in situ hybridization method (mFISH). An increase in the number of CAs was observed with the accumulation of RAI activity. The yield of these CAs per unit of accumulated RAI activity was, however, approximately three-fold lower than the respective yield for the incremented number of CAs in a selected course, thus demonstrating the elimination of CAs and/or aberrant cells with time. Biological dosimetry was performed based on the number of all types of CAs and in vitro mFISH calibration curves. With an average administered RAI activity of 3.40 ± 0.39 GBq, the average absorbed blood dose was 0.61 Gy (0.31-0.89:95% CI). Our results demonstrate that one-time administration of such activities of RAI was safe, since the commonly accepted threshold of 2 Gy for the blood dose was not exceeded.